🔥 This Cancer-Prevention Vaccine Kept Every Patient Clear of Colon Cancer — and Just Raised $135 Million

Picture getting a cheap genetic test back and learning your lifetime odds of colon cancer sit somewhere between 40% and 80% — not the roughly 5% everyone else walks around with. That’s the hand dealt to people born with Lynch syndrome, and there are more of them than you’d guess: about 1 in 279 people carry it (MD Anderson).

Now picture a shot that teaches your immune system to hunt that cancer down before it ever appears. On Monday, a Basel biotech called Nouscom raised €120 million ($135 million) to find out whether that shot really works at scale (Fierce Biotech).

Here’s the figure that loosened investors’ purse strings: in an early trial, every evaluable patient who got the vaccine stayed free of advanced polyps and colorectal cancer a year after treatment (Nature Medicine, via MD Anderson).

Cancer prevention is quietly turning into something you can buy shares in.

🧠 Why This Matters

Most of the cancer-vaccine noise you’ve heard over the past few years has been about treating tumors that already exist — shrinking them, stopping them from coming back. This is a different bet. NOUS-209 is aimed at interception: catching the disease in people who are almost certain to get it, before there’s anything to cut out.

That matters because the current playbook for Lynch carriers is grim and exhausting. You either get a colonoscopy every year or two for the rest of your life, or you book elective surgery to remove organs you’d rather keep. As the trial’s lead investigator put it:

“By teaching the immune system to recognize and attack abnormal cells, this therapy offers a promising new approach.” — Eduardo Vilar-Sanchez, M.D., Ph.D., MD Anderson

If a few jabs can do even part of what a lifetime of scopes does, the quality-of-life math changes for millions of people. And because Lynch syndrome shows up young — carriers often get cancer well before the general population does — the window to intervene is wide.

📊 Deep Dive

NOUS-209 is what’s called an off-the-shelf vaccine, and that word is doing a lot of work. Most cutting-edge cancer vaccines are personalized: a lab sequences your specific tumor, then brews a bespoke shot just for you. Nouscom’s approach is the opposite — one standardized product designed to work across carriers, no custom manufacturing required (Fierce Biotech).

It pulls that off by targeting the predictable mistakes Lynch tumors make. These cancers are mismatch-repair deficient, meaning the cell’s spell-checker is broken, so they churn out the same garbled protein fragments over and over. NOUS-209 uses two viral vectors to deliver 209 shared frameshift neoantigens — a wanted poster for exactly those recurring errors.

The numbers behind the raise and the science:

• €120M / $135M — the Series D, co-led by M Ventures and Revelation Partners (finsmes)
• New backers: Angelini Industries, the European Investment Bank, and Neva SGR, alongside existing investors 5AM Ventures and Andera Partners (Fierce Biotech)
• 45 participants in the Phase 1b/2 trial, with one-year data on 43 and two-year data on 17 (Fierce Biotech)
• 209 shared frameshift neoantigens packed into two viral vectors
• 1 in 279 people carry Lynch syndrome; colorectal risk runs 60–80% in men and 40–60% in women (MD Anderson)

The immune response held up, too: patients produced broad, durable anti-neoantigen T-cell responses, and an annual booster made them stronger rather than fizzling out (MD Anderson).

⚠️ The Catch

Slow down before you declare cancer solved. The eye-popping “everyone stayed clear” result comes from a Phase 1b/2 trial of 45 people that was built mainly to check safety and immune response — not to prove the vaccine actually prevents cancer (MD Anderson).

That’s a small group over a short stretch. Lynch cancers can take years to surface, so “no advanced polyps at one year” is an encouraging signal, not a verdict. Nouscom itself described the data as an “encouraging signal of durable clinical activity” — careful wording that tells you the big question is still open (Fierce Biotech).

The whole point of the $135 million is to run the trial that could actually settle it — larger, longer, and designed to win regulators over. Plenty of promising immunotherapies have looked great in a tiny early study and then flattened out when the numbers got bigger. This could be the one that doesn’t. It could also not be.

🎯 What Happens Next

The money funds a global, registration-enabling trial — biotech-speak for the pivotal study that regulators would use to decide whether NOUS-209 can be sold (techstartups). That’s a years-long commitment, which is why Nouscom needed a nine-figure cushion rather than a top-up.

Watch two things. First, enrollment and follow-up: a prevention trial has to track healthy-ish carriers long enough to see whether cancers that should appear simply don’t. Second, the booster cadence — if a yearly shot really does keep stacking the immune response, that’s a far easier sell than annual colonoscopies.

The European Investment Bank showing up on the cap table is its own tell. Public-money lenders don’t chase hype; they like projects with a clear public-health payoff. Read that as institutional confidence that cancer interception is a category worth funding, not just a single hopeful drug.

🧩 Bigger Picture

For a decade, the dream of a “cancer vaccine” mostly meant mopping up after diagnosis. The frontier is shifting toward stopping the disease in people we can identify as high-risk long before symptoms — and Lynch syndrome, with its known genetics and sky-high odds, is the perfect proving ground.

If NOUS-209 clears its pivotal trial, the template travels. The same shared-mutation logic could apply to other hereditary cancer syndromes, and eventually to anyone whose genetics hand them a loaded deck. An off-the-shelf shot is also the kind of thing a health system can actually afford to give at scale, unlike a bespoke, per-patient brew.

That’s the quiet revolution hiding inside a Monday funding announcement: medicine inching from detect and treat toward predict and prevent.

A vaccine that cancels your cancer before you ever feel it would be the rarest thing in oncology — boring. And boring, when it comes to cancer, would be the best news in years.

---

Sources

• Fierce Biotech — Nouscom raises $135M for pivotal trial of cancer-preventing vaccine candidate
• MD Anderson Newsroom — Immune-targeting vaccine shows promise intercepting cancer in patients with Lynch syndrome
• MD Anderson — Lynch syndrome: 10 things to know
• finsmes — Nouscom Raises €120M in Series D Funding
• Tech Startups — Startup Funding News Today, October 19, 2026

❓ Quick answers

What is NOUS-209 and what did Nouscom's $135 million fund?

NOUS-209 is an off-the-shelf cancer-prevention vaccine using two viral vectors to deliver 209 shared frameshift neoantigens. On Oct 19, 2026, Nouscom raised €120M ($135M) to run a global, registration-enabling trial (Fierce Biotech).

How well did the NOUS-209 vaccine work in trials?

In a 45-patient Phase 1b/2 trial, all evaluable Lynch syndrome carriers were free of advanced polyps and colorectal cancer at one year, with durable T-cell responses, published in Nature Medicine on Jan 16, 2026 (MD Anderson).

How common is Lynch syndrome and how risky is it?

About 1 in 279 people carry Lynch syndrome, which raises lifetime colorectal cancer risk to 60-80% in men and 40-60% in women, versus about 5% in the general population (MD Anderson).